Traders Buy Large Volume of Call Options on Assembly Biosciences (NASDAQ:ASMB)

Assembly Biosciences Inc (NASDAQ:ASMB) was the recipient of unusually large options trading activity on Monday. Investors bought 2,402 call options on the company. This represents an increase of 1,411% compared to the typical volume of 159 call options.

ASMB has been the topic of a number of research reports. ValuEngine raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Chardan Capital reissued a “neutral” rating on shares of Assembly Biosciences in a report on Thursday, September 19th. BidaskClub raised shares of Assembly Biosciences from a “strong sell” rating to a “sell” rating in a report on Thursday, October 17th. William Blair reissued a “buy” rating on shares of Assembly Biosciences in a report on Thursday, November 7th. Finally, Zacks Investment Research raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating and set a $13.00 price objective on the stock in a report on Friday, September 27th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $36.40.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Nuveen Asset Management LLC purchased a new stake in shares of Assembly Biosciences during the second quarter valued at $3,681,000. Citadel Advisors LLC lifted its stake in Assembly Biosciences by 90.0% in the second quarter. Citadel Advisors LLC now owns 450,315 shares of the biopharmaceutical company’s stock worth $6,075,000 after acquiring an additional 213,363 shares during the period. Vanguard Group Inc. lifted its stake in Assembly Biosciences by 13.6% in the second quarter. Vanguard Group Inc. now owns 1,226,953 shares of the biopharmaceutical company’s stock worth $16,552,000 after acquiring an additional 146,452 shares during the period. Rock Springs Capital Management LP lifted its stake in Assembly Biosciences by 24.4% in the second quarter. Rock Springs Capital Management LP now owns 560,000 shares of the biopharmaceutical company’s stock worth $7,554,000 after acquiring an additional 110,000 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in Assembly Biosciences by 338.5% in the second quarter. Renaissance Technologies LLC now owns 133,300 shares of the biopharmaceutical company’s stock worth $1,798,000 after acquiring an additional 102,900 shares during the period. Institutional investors own 81.21% of the company’s stock.

Shares of Assembly Biosciences stock traded down $0.20 on Tuesday, hitting $14.28. 24,155 shares of the company traded hands, compared to its average volume of 1,133,212. The stock has a market capitalization of $444.88 million, a P/E ratio of -3.59 and a beta of 1.58. The company has a debt-to-equity ratio of 0.06, a quick ratio of 7.69 and a current ratio of 7.69. Assembly Biosciences has a 52 week low of $8.13 and a 52 week high of $27.60. The business has a 50-day simple moving average of $12.98 and a 200 day simple moving average of $13.56.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.93) by ($0.03). Assembly Biosciences had a negative net margin of 647.72% and a negative return on equity of 52.83%. The company had revenue of $4.23 million for the quarter, compared to the consensus estimate of $3.45 million. Research analysts expect that Assembly Biosciences will post -3.64 earnings per share for the current year.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

Recommended Story: How To Calculate Debt-to-Equity Ratio

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.